Emergent BioSolutions | EBS - Capital Ordinário





Capital Ordinário Alterar Data
Acadia Pharmaceuticals USD 169.18M 470K 2025-12
Akebia Therapeutics USD 265.42M 199K 2025-12
ALKERMES USD 166.46M 855K 2026-03
Alnylam Pharmaceuticals USD 133.44M 1.07M 2026-03
Amarin USD 20.81M 13K 2025-12
ANI Pharmaceuticals USD 22.49M 760K 2025-12
BioMarin Pharmaceutical USD 193.27M 969K 2026-03
Coherus Biosciences USD 121.16M 4.92M 2025-12
Emergent BioSolutions USD 100K 0 2023-06
Exelixis USD 253.7M 8.78M 2026-03
Glaxosmithkline GBP 4.08B 49.43M 2025-12
Heron Therapeutics USD 188.31M 4.99M 2025-12
Ionis Pharmaceuticals USD 165.9M 3.93M 2026-03
Ironwood Pharmaceuticals USD 160K 0 2024-12
Lexicon Pharmaceuticals USD 363.47M 67K 2025-12
Lonza CHF 68.64M 0 2025-12
Merck USD 2.47B 12.72M 2025-12
Moderna USD 391M 2M 2025-09
Myriad Genetics USD 93.5M 400K 2025-12
Nektar Therapeutics USD 20.38M 20.36M 2025-12
Neurocrine Biosciences USD 100.6M 500K 2026-03
Pacira USD 39.31M 1.81M 2026-03
Pfizer USD 5.7B 13M 2026-03
PTC Therapeutics USD 81.47M 1.54M 2025-12
Sanofi EUR 1.21B 8.25M 2026-03
Sarepta Therapeutics USD 105.57M 607K 2026-03
United Therapeutics USD 42.16M 1.49M 2026-03
Vanda Pharmaceuticals USD 58K 0 2024-12
Xoma USD 87K 1000 2024-06